No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
CN Stock MarketDetailed Quotes
600436 Zhangzhou Pientzehuang Pharmaceutical
- 230.60
- -0.46-0.20%
Trading Jul 22 10:16 CST
139.12BMarket Cap46.34P/E (TTM)
232.28High227.77Low9.48KlotVolume230.81Open231.06Pre Close218.16MTurnover0.16%Turnover Ratio49.73P/E (Static)603.32MShares296.1852wk High10.76P/B139.12BFloat Cap178.3752wk Low254.17Limit Up603.32MShs Float487.10Historical High207.95Limit Down1.95%Amplitude-6.18Historical Low2.32Dividend TTM230.17Avg Price3.58KlotAsk1.01%Div YieldTTM100Lot Size4.41KlotBid
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Stock Performs Better Than Its Underlying Earnings Growth Over Last Five Years
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose your money. But on a lighter note, a good company can see its share price rise
Bullish news! Margin trading and securities lending temporarily suspended!
A very heavy means of attacking short sellers.
Pientzehuang Pharmaceutical Gets Nod to Trails Lymphoma Drug
Zhangzhou Pientzehuang Pharmaceutical (SHA:600436) will conduct clinical trials on PZH2113 capsules after receiving approval from China's National Medical Products Administration, the company said in
Estimating The Fair Value Of Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436)
Key Insights Zhangzhou Pientzehuang Pharmaceutical's estimated fair value is CN¥224 based on 2 Stage Free Cash Flow to Equity With CN¥213 share price, Zhangzhou Pientzehuang Pharmaceutical appears t
Zhangzhou Pientzehuang Pharmaceutical (600436.SH): received the "Drug Clinical Trial Approval Notice" for PZH2113 capsule.
On June 20th, Gelonhui announced that it had received the Approval Notice for Clinical Trials of PZH2113 Capsule, a new drug for chemical drugs of type 1 innovative drugs with independent intellectual property rights. The company still needs to conduct clinical trials and obtain approval from the National Medical Products Administration before it can be produced and launched. This drug is mainly used for the treatment of relapsed/refractory non-Hodgkin's lymphoma, mainly diffuse large B-cell lymphoma. According to the relevant registration regulations for innovative drugs of type 1 in the new registration classification of chemical drugs, the company has completed the P.
Is It Smart To Buy Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) Before It Goes Ex-Dividend?
Readers hoping to buy Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) for its dividend will need to make their move shortly, as the stock is about to trade ex-dividend. The ex-dividend date
Comments
Despite a recent drop, Zhangzhou Pientzehuang Pharmaceutical's long-term returns remain impressive. The market sentiment remains steady, reflecting the EPS growth. The current sell-off could be an opportunity if sustainable growth continues.
Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Shareholders Have Earned a 17% CAGR Over the Last Five YearsZhangzhou Pientzehuang Pharmaceutical's performance is commendable, with efficient reinvestment of its earnings leading to impressive earnings growth. The company's earnings growth is expected to continue at a similar rate, according to analyst forecasts.
Zhangzhou Pientzehuang Pharmaceutical investors remain upbeat despite high P/E ratio. However, comfort is wavering due to the difficulty of justifying these prices long-term without substantial growth rate improvements.
Zhangzhou Pientzehuang Pharmaceutical's share price reflects steady EPS growth indicating investor sentiment continuity. It appears that shareholders are rewarded generously via dividends, as suggested by total shareholder returns exceeding share price return.
Read more
Analysis
Price Target
No Data
Heat List
CN
Overall
Symbol
Latest Price
%Chg